GET DAILY SIGNALSAbsci Corporation (ABSI) Reports Wider Q3 Loss as Pipeline Catalyst Looms
Key Takeaways
- Absci Corporation reported a third quarter 2026 net loss of $33.3 million, compared with $28.7 million in the prior-year period.
- GAAP loss per share came in at $0.19, roughly in line with analyst consensus of a $0.19 loss, while revenue of about $0.3 million fell short of expectations.
- Research and development (R&D) expense rose to $23.6 million from $19.2 million a year earlier, driven by advancement of the ABS-201 clinical program.
- Cash, cash equivalents, and marketable securities stood at $173.7 million as of September 30, 2026, with runway guided into the second half of 2028.
- Management reaffirmed a 13-week interim proof-of-concept readout for ABS-201 in pattern hair loss expected in December 2026.
- For additional context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast.
- Discover how automated strategies approach this stock by exploring Trending AI Robots.
Earnings Context and Why It Matters
Absci Corporation is a clinical-stage biopharmaceutical company that designs therapeutics using generative artificial intelligence (AI). For a company of this profile, quarterly revenue is far less meaningful than clinical progress, cash runway, and pipeline momentum. The third quarter 2026 update matters because investors are focused on ABS-201, the company's lead candidate for pattern hair loss, ahead of a 13-week interim proof-of-concept data readout slated for December. Rising R&D spending reflects a deeper commitment to that program, while a shifted timeline for the endometriosis trial adds a layer of scrutiny. The report offers a snapshot of how quickly ABSI is consuming capital as it advances toward a high-stakes clinical catalyst.
Reported Results
For the three months ended September 30, 2026, Absci reported a net loss of $33.3 million, widening from $28.7 million in the same quarter a year ago. On a per-share basis, both basic and diluted loss from continuing operations were $0.19, compared with $0.20 a year earlier, reflecting a higher weighted share count rather than a smaller underlying loss.
Revenue came in at approximately $0.3 million, below analyst expectations that were closer to $0.7 million. The loss per share of $0.19 was broadly in line with consensus estimates. R&D expenses increased to $23.6 million from $19.2 million, driven primarily by external nonclinical and clinical development costs for ABS-201, partially offset by lower personnel-related costs. Selling, general, and administrative (SG&A) expenses were $9.0 million, up from $8.4 million, largely due to stock-based compensation.
The company ended the quarter with $173.7 million in cash, cash equivalents, and marketable securities, down from $201.1 million at June 30, 2026. Management reiterated that this balance is expected to fund operations into the second half of 2028. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
The stock traded lower following the report, with early indications pointing to a mid-to-high single-digit decline in the premarket session. For a clinical-stage biotech, investors appeared to weigh the revenue miss and rising cash burn against the more meaningful pipeline developments. The reaffirmed December interim data timeline for ABS-201 provided a concrete near-term catalyst, but a delay in the planned Phase 2 endometriosis trial start, now guided to mid-2027, tempered enthusiasm. The appointment of a first-ever Chief Commercial Officer signaled a step toward building direct-to-consumer infrastructure, though the market's focus remains squarely on the upcoming hair-loss efficacy data.
Forward Outlook and Key Factors to Monitor
The primary catalyst for Absci is the 13-week interim proof-of-concept readout for ABS-201 in pattern hair loss, anticipated in December 2026, followed by full 26-week data in early 2027. Investors will be watching whether early signs of regenerative hair growth emerge and how those results compare with competitive benchmarks in the broader hair-loss treatment landscape.
Beyond the headline data, attention will shift to the STORYLINE Phase 2 trial in endometriosis, which management now expects to initiate in mid-2027. Because the trial's dosing design depends on data from the pattern hair loss program, the two indications remain closely linked, and any delays in the lead program could cascade.
On the financial side, rising R&D spending and a shrinking cash balance mean capital efficiency will be a recurring theme. The company's guided runway into the second half of 2028 provides flexibility, but the pace of burn will be scrutinized as clinical programs expand. Finally, the build-out of commercial capabilities under the new Chief Commercial Officer offers an early signal of how Absci plans to position ABS-201 for a direct-to-consumer market, should clinical development prove successful. From what I see, this is important because it ties directly into long-term positioning.
Exploring AI Tools for Biotech Analysis
In my view, incorporating AI-driven screening tools into the research process helps cut through the noise when evaluating clinical-stage names like ABSI. I find that reviewing technical patterns alongside fundamentals gives a clearer picture of how peers are positioned ahead of key readouts. One thing that stands out is how these platforms can highlight comparable opportunities in the sector without requiring hours of manual work.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ABSI sees its Stochastic Oscillator ascending out of oversold territory
On November 09, 2026, the Stochastic Oscillator for ABSI moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 60 instances where the indicator left the oversold zone. In 59 of the 60 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
ABSI moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ABSI crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 20 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +15.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABSI advanced for three days, in 242 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 141 of 175 cases where ABSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABSI as a result. In 85 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ABSI turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 42 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
ABSI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ABSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.091) is normal, around the industry mean (3.498). P/E Ratio (-12.873) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (769.231) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement